Findings

What do systematic reviews say?

62 questions · 63 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 20.6%GRADE not reported 1 · 1.6%Very low 13 · 20.6%Low 28 · 44.4%Moderate 8 · 12.7%High 0 · 0%

Macrolides vs placebo

Outcomesa · adults and children with chronic asthma

The review found no eligible studies for this question.

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs placebo

Severe exacerbations requiring hospitalisation over the study period · adults and children with chronic asthma

Macrolides showed no clear difference in exacerbation requiring hospitalisation Weighted mean study duration:… compared with placebo (moderate certainty).

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
OR 0.47 [0.2, 1.12]
2 studies · 529 participants
Moderate

Severe exacerbations (requiring ED visits or systemic steroids, or both) Number of people having ≥ 1 exacerbations requiring an ED visit or systemic steroids, or both. Classification varied across studies. Weighted mean study duration: 35 weeks · adults and children with chronic asthma

Macrolides probably leads to lower severe exacerbations (requiring ED visits or systemic steroids, or… compared with placebo (moderate certainty).

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
Rate ratio 0.65 [0.53, 0.8]
4 studies · 640 participants
Moderate

Macrolides vs placebo

Asthma symptoms · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 136 participants
Very low

Macrolides vs placebo

Asthma control · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 773 participants
Low

Macrolides vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 802 participants
Very low

Macrolides vs placebo

Use of rescue medication · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 314 participants
Low

Macrolides vs placebo

FEV1 (L) Weighted mean study duration: 28 weeks · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1046 participants
Low

Macrolides vs placebo

Serious adverse events (including mortality) · adults and children with chronic asthma

Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
OR 0.8 [0.49, 1.31]
8 studies · 854 participants
Low

Macrolides vs other antibiotics

Clinical cure: syndromic approach · sexually active adults

Macrolides showed no clear difference in clinical cure: syndromic approach compared with any other antibiotic (low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 1.09 [0.97, 1.21]
2 studies · 340 participants
Low

Macrolides vs other antibiotics

Clinical cure: aetiological approach · sexually active adults

Macrolides showed no clear difference in clinical cure: aetiological approach compared with any other antibiotic (low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 1.06 [0.98, 1.15]
5 studies · 348 participants
Low

Macrolides vs other antibiotics

Clinical improvement: syndromic approach · sexually active adults

It is very uncertain whether macrolides changes clinical improvement: syndromic approach compared with any other antibiotic (very low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 0.89 [0.52, 1.52]
2 studies · 340 participants
Very low

Macrolides vs other antibiotics

Clinical improvement: aetiological approach · sexually active adults

Macrolides showed no clear difference in clinical improvement: aetiological approach compared with any other antibiotic (low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 0.8 [0.42, 1.51]
3 studies · 187 participants
Low

Macrolides vs other antibiotics

Microbiological cure · sexually active adults

Macrolides showed no clear difference in microbiological cure compared with any other antibiotic (low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 0.93 [0.74, 1.16]
1 study · 45 participants
Low

Macrolides vs other antibiotics

Minor adverse events · sexually active adults

It is very uncertain whether macrolides changes minor adverse events compared with any other antibiotic (very low certainty).

1 finding from 1 review

Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes only
RR 1.34 [0.24, 7.51]
3 studies · 412 participants
Very low

Macrolides vs penicillin

Resolution of symptoms post‐treatment (ITT analysis) · group A streptococcal pharyngitis

Macrolides showed no clear difference in resolution of symptoms post‐treatment (ITT analysis) compared with penicillin (low certainty).

1 finding from 1 review

Different antibiotic treatments for group A streptococcal pharyngitis 2023 · Cochrane Headline outcomes only
OR 1.11 [0.92, 1.35]
6 studies · 1728 participants
Low

Macrolides vs penicillin

Resolution of symptoms post‐treatment (evaluable participants) · group A streptococcal pharyngitis

Macrolides showed no clear difference in resolution of symptoms post‐treatment (evaluable participants) compared with penicillin (low certainty).

1 finding from 1 review

Different antibiotic treatments for group A streptococcal pharyngitis 2023 · Cochrane Headline outcomes only
OR 0.79 [0.57, 1.09]
6 studies · 1159 participants
Low

Macrolides vs penicillin

Relapse · group A streptococcal pharyngitis

Macrolides showed no clear difference in incidence of relapse (evaluable participants) compared with penicillin (low certainty).

1 finding from 1 review

Different antibiotic treatments for group A streptococcal pharyngitis 2023 · Cochrane Headline outcomes only
OR 1.21 [0.48, 3.03]
6 studies · 802 participants
Low

Macrolides vs penicillin

Adverse events (ITT analysis) · group A streptococcal pharyngitis

Macrolides showed no clear difference in adverse events (ITT analysis) compared with penicillin (low certainty).

1 finding from 1 review

Different antibiotic treatments for group A streptococcal pharyngitis 2023 · Cochrane Headline outcomes only
OR 1.19 [0.82, 1.73]
6 studies · 1727 participants
Low

Macrolides vs doxycycline

Serious adverse events · adults and adolescents with scrub typhus

1 finding from 1 review

Antibiotics for treating scrub typhus 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 242 participants
Very low